TORONTO, ON / ACCESSWIRE / October 29, 2015 / CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm Solutions" or the "Company") a global medical provider of consumer heart monitoring and medical electrocardiogram ("ECG") software solutions, today confirmed that is has signed a marketing and sales agreement with UAE-based Europtima Medical Solutions FZ, LLC ("EMS"), a company dedicated to provide medical technology, hardware and software solutions to hospitals, private clinics and other medical facilities in several middle east countries as well as Africa and Europe.
With offices globally, EMS leverages their 25 years of experience to find and introduce innovative medical solutions and to provide complete, state-of-the-art, high quality medical end-to-end solutions to their customers in the medical industry. Armed with great relationships with R&D institutes internationally, EMS has established strategic alliances with inventors and innovators worldwide. "We at EMS scout and identify breakthrough technologies that are game changers and disrupting the medical care delivery status quo, then we bring them to our established networks", says Ray Kattar CEO of EMS. The CardioComm Solutions Agreement is EMS' most recent partnership undertaking.
The Marketing and Sales Agreement was executed in July 2015 however the collaborative kick off occurred in October with EMS introducing and launching preventative ECG monitoring solutions involving the HeartCheck(TM) PEN and GEMS(TM) WIN technologies. There is an emphasis on reducing the effects of Atrial Fibrillation ("AF") with clients within countries under the Gulf Cooperation Council ("GCC"), as well as the rest of the Middle East and North Africa ("MENA") region including Jordan, Iran, Palestine, Lebanon, Morocco, Egypt and Libya.
CardioComm Solutions' technologies will form an integral part of EMS' product portfolio and strategy and the two companies are working to develop a roadmap to place the Company's ECG management technologies and monitoring services as competitively priced, high-value solutions to EMS customers to ensuring their growth, profitability and continuity of medical excellence. The target customers are hospital-based electrophysiology ("EP") labs and cardiac centers, cardiology and internal medicine private clinics and retail chain pharmacies.
EMS has trained their sales teams on the CardioComm Solutions offerings, as well as developed a comprehensive go-to-market plan for building awareness in the region through participation in key conferences, symposiums, product demos and other strategic marketing activities. EMS has also confirmed that several pilot and proof-of-concept projects are also underway.
Appropriate medical device certifications, such as FDA clearances, are required for medical solutions to be sold within the GCC and MENA regions. CardioComm Solutions' GEMS(TM) WIN ECG management solutions and the cost effect HeartCheck(TM) ECG device, GEMS(TM) Home and SMART Monitoring ECG services will provide healthcare organizations within these regions to implement arrhythmia screening and treatment procedure in a standardized fashion and similar to those applied within North America.
The Company plans to continue with a set of structured campaigns to expand customer and investor awareness of its consumer and hospital biotechnology, health and wellness and heart monitoring innovations across a broader cross-section. To learn more about CardioComm Solutions' consumer HeartCheck(TM) ECG products and their hospital-based ambulatory cardiac arrhythmia technologies GEMS(TM) WIN, please see the Company's websites at www.theheartcheck.com and www.cardiocommsolutions.com.
About CardioComm Solutions
CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms (ECGs) for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. The Company has earned the ISO 13485 certification, is HPB approved, HIPAA compliant, and has received FDA market clearance for its software devices. CardioComm Solutions is headquartered in Toronto, Ontario, Canada.
FOR FURTHER INFORMATION PLEASE CONTACT:
CardioComm
Etienne Grima, Chief Executive Officer
1-877-977-9425 x 227
investorrelations@cardiocommsolutions.com
www.cardiocommsolutions.com
About Europtima Medical Solutions
EMS is the spinoff company from Europtima, an European 25 years old Group known for its successful multi-sectors real estate developments across EMENA and GCC regions. EMS is fully dedicated to bring innovative but selective medical technologies to its markets; it advises senior Healthcare authorities, designs and implements solutions, and bridges the gap between Medical inventors and buyers.
FOR FURTHER INFORMATION PLEASE CONTACT:
EMS
Ray Kattar, Chief Executive Officer
+971 56 624 1815
Info@europtimamedical.com
www.europtima.com
Forward-looking statements
This release may contain certain forward-looking statements and forward looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.
In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation Section 5.8(2) of National Instrument 51-102 (Continuous Disclosure Obligations).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: CardioComm Solutions, Inc.
